Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

This study found that initiating low-dose oral minoxidil did not significantly change alcohol consumption among 21,971 patients, suggesting a minimal impact on alcohol-related hangover symptoms.

This letter to the editor discusses blood pressure changes in patients taking low-dose oral minoxidil but reports no new research findings.

This study found that adding low-dose oral minoxidil to standard treatment for lichen planopilaris was safe but did not significantly improve hair density or thickness, although minor hair regrowth was observed in some scarring areas.

This source reports that an international panel of dermatologists has provided a consensus statement to guide clinicians on the off-label use of low-dose oral minoxidil for treating hair loss.

In this study of patients with androgenetic alopecia taking off-label low-dose oral minoxidil, adverse events like dizziness/lightheadedness, hypertrichosis, and extremity edema were observed in 14.9% of patients, with females experiencing more adverse events; higher doses increased dizziness risk, leading researchers to recommend cautious dosing approaches.

This consensus statement provides expert guidance on prescribing low-dose oral minoxidil for hair loss, noting a lack of representation of pediatric specialists and highlighting areas for future research.

This study examined the FDA Adverse Event Reporting System database and found significant associations between low-dose oral minoxidil use and adverse events like pericardial effusion, highlighting the need for caution and recommending the use of the lowest effective dose until more safety data are available.

This study found that administering a supraphysiological dose of testosterone to female rats significantly reduced estrogen and progesterone levels, disrupted sex steroid receptor expression, and interfered with the embryonic implantation window, indicating potential implications for androgen-related endometrial conditions.

Both treatment combinations improved hair growth similarly and were safe.

In this case series, low-dose oral metformin was associated with improvements in symptoms and gene expression changes in Black female patients with treatment-resistant central centrifugal cicatricial alopecia, suggesting a potential therapeutic role for metformin in managing this condition.

This study addresses the scarcity of information on the effectiveness and safety of low-dose oral minoxidil for treating COVID-19-associated telogen effluvium, a type of hair loss observed in some patients after COVID-19 infection, but does not report specific results.

This review discusses the consensus reached by international experts on guidelines for prescribing and monitoring low-dose oral minoxidil for hair loss, and reports no new clinical results.

In this study, low-dose oral minoxidil was found to be an effective and safe treatment for androgenetic alopecia, showing comparable outcomes in patients with AGA alone and those with AGA unmasked by telogen effluvium.

This case study involving a 63-year-old woman with female pattern hair loss found that a 3-month regimen of low-dose oral minoxidil increased hair density from 98 to 140 hairs per square centimeter, but caution was advised regarding its safety and efficacy without larger trials.

Low-dose oral minoxidil is generally safe for hypertensive patients with hair loss.

In this study, researchers found that low-dose oral minoxidil for androgenetic alopecia in men generally showed a good safety profile, with hypertrichosis being the most frequent side effect, while systemic side effects like dizziness and hypotension were less common and no life-threatening effects were observed.

Low-dose oral minoxidil is safe for alopecia patients, even those prone to edema.

This nested case-control study observed that patients with benign prostatic hyperplasia or androgenic alopecia who had a cumulative 5-ARI dose exceeding 5840 defined daily doses had a significantly reduced mortality risk, while lower doses were linked to higher mortality and suicide rates.

This study found that combining platelet-rich plasma with topical minoxidil led to the greatest increase in terminal hair density at 32 weeks, while low-dose oral minoxidil was more effective at reducing vellus hair density in men with androgenetic alopecia.

The study found that combining platelet-rich plasma with topical minoxidil significantly improved terminal hair density in androgenetic alopecia patients, while low-dose oral minoxidil was more effective at reducing vellus hair density.

In this study, conducted on male Wistar rats, high doses of white turi flower extract significantly increased sodium and potassium kidney levels, causing symptoms like lethargy and hair loss without fatalities, suggesting potential acute toxicity that warrants further research for long-term safety assessment.

Low-dose minoxidil helps hair grow longer and thicker in people with short anagen syndrome.

In this case study, a 19-year-old woman with Henoch-Schönlein purpura, potentially triggered by hepatitis B vaccination, experienced improved symptoms after correcting low vitamin D levels and undergoing tonsillectomy, demonstrating these interventions may benefit similar patients.

In this study, a survey of 84 Saudi Arabian dermatologists found increasing use of low-dose oral Minoxidil for hair loss management, though the limited sample size and English questionnaire may affect how well the findings represent the entire dermatologist population in the country.

Low-dose spironolactone can be effective for treating hair loss in women.

Among Saudi dermatologists, this study reported widespread recognition of low-dose oral minoxidil's use for patterned hair loss and its side effect of hypertrichosis; however, many avoid prescribing it due to its unavailability in local pharmacies.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

This article discusses the use of low-dose oral minoxidil as an off-label treatment for androgenetic alopecia but reports no new clinical results.